• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中黏液层与肠道微生物群的相互作用:土壤与种子。

Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds.

机构信息

Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, China.

Department of School of Life Sciences, Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310053, China.

出版信息

Chin Med J (Engl). 2023 Jun 20;136(12):1390-1400. doi: 10.1097/CM9.0000000000002711. Epub 2023 May 18.

DOI:10.1097/CM9.0000000000002711
PMID:37200041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10278733/
Abstract

The intestinal mucus layer is a barrier that separates intestinal contents and epithelial cells, as well as acts as the "mucus layer-soil" for intestinal flora adhesion and colonization. Its structural and functional integrity is crucial to human health. Intestinal mucus is regulated by factors such as diet, living habits, hormones, neurotransmitters, cytokines, and intestinal flora. The mucus layer's thickness, viscosity, porosity, growth rate, and glycosylation status affect the structure of the gut flora colonized on it. The interaction between "mucus layer-soil" and "gut bacteria-seed" is an important factor leading to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Probiotics, prebiotics, fecal microbiota transplantation (FMT), and wash microbial transplantation are efficient methods for managing NAFLD, but their long-term efficacy is poor. FMT is focused on achieving the goal of treating diseases by enhancing the "gut bacteria-seed". However, a lack of effective repair and management of the "mucus layer-soil" may be a reason why "seeds" cannot be well colonized and grow in the host gut, as the thinning and destruction of the "mucus layer-soil" is an early symptom of NAFLD. This review summarizes the existing correlation between intestinal mucus and gut microbiota, as well as the pathogenesis of NAFLD, and proposes a new perspective that "mucus layer-soil" restoration combined with "gut bacteria-seed" FMT may be one of the most effective future strategies for enhancing the long-term efficacy of NAFLD treatment.

摘要

肠黏液层是分隔肠内容物和上皮细胞的屏障,也是肠道菌群黏附定植的“黏液层-土壤”。其结构和功能完整性对人体健康至关重要。肠黏液受饮食、生活习惯、激素、神经递质、细胞因子和肠道菌群等因素的调节。黏液层的厚度、黏度、孔隙率、增长率和糖基化状态影响着定植其上的肠道菌群结构。“黏液层-土壤”与“肠道细菌-种子”的相互作用是导致非酒精性脂肪性肝病(NAFLD)发病的重要因素。益生菌、益生元、粪便微生物移植(FMT)和灌洗微生物移植是治疗 NAFLD 的有效方法,但长期疗效不佳。FMT 专注于通过增强“肠道细菌-种子”来实现治疗疾病的目标。然而,缺乏对“黏液层-土壤”的有效修复和管理可能是“种子”不能在宿主肠道中良好定植和生长的原因,因为“黏液层-土壤”的变薄和破坏是非酒精性脂肪性肝病的早期症状。本综述总结了肠道黏液与肠道菌群之间的现有相关性,以及非酒精性脂肪性肝病的发病机制,并提出了一个新的观点,即“黏液层-土壤”的修复与“肠道细菌-种子”的 FMT 相结合可能是增强非酒精性脂肪性肝病治疗长期疗效的最有效策略之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/7116f0b74240/cm9-136-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/4582ea06142d/cm9-136-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/7116f0b74240/cm9-136-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/4582ea06142d/cm9-136-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/7116f0b74240/cm9-136-1390-g002.jpg

相似文献

1
Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds.非酒精性脂肪性肝病中黏液层与肠道微生物群的相互作用:土壤与种子。
Chin Med J (Engl). 2023 Jun 20;136(12):1390-1400. doi: 10.1097/CM9.0000000000002711. Epub 2023 May 18.
2
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.综述文章:细菌可以成为药物吗?益生菌和益生元作为非酒精性脂肪性肝病治疗手段的潜力。
Aliment Pharmacol Ther. 2019 Sep;50(6):628-639. doi: 10.1111/apt.15416. Epub 2019 Aug 2.
3
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.肠道微生物组与非酒精性脂肪性肝病:分子见解与治疗展望。
J Gastroenterol. 2020 Feb;55(2):142-158. doi: 10.1007/s00535-019-01649-8. Epub 2019 Dec 16.
4
Gut microbiome and non-alcoholic fatty liver disease.肠道微生物组与非酒精性脂肪性肝病。
Prog Mol Biol Transl Sci. 2022;191(1):187-206. doi: 10.1016/bs.pmbts.2022.07.004. Epub 2022 Aug 22.
5
Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.非酒精性脂肪性肝病:从肠道微生物群作用到基于微生物的治疗方法。
Eur J Clin Microbiol Infect Dis. 2020 Apr;39(4):613-627. doi: 10.1007/s10096-019-03746-1. Epub 2019 Dec 11.
6
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群:非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
7
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.非酒精性脂肪性肝病与肠道微生物失调:潜在机制和肠道微生物介导的治疗策略。
Rev Endocr Metab Disord. 2023 Dec;24(6):1189-1204. doi: 10.1007/s11154-023-09843-z. Epub 2023 Oct 16.
8
Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.通过以肠道微生物组为中心的疗法靶向非酒精性脂肪性肝病。
Gut Microbes. 2023 Jan-Dec;15(1):2226922. doi: 10.1080/19490976.2023.2226922.
9
Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).用营养干预、益生菌、合生菌和粪便微生物群移植(FMT)来对抗脂肪肝疾病。
Adv Exp Med Biol. 2019;1125:85-100. doi: 10.1007/5584_2018_318.
10
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.非酒精性脂肪性肝病的治疗进展:以微生物组为中心的观点。
World J Gastroenterol. 2020 Apr 28;26(16):1901-1911. doi: 10.3748/wjg.v26.i16.1901.

引用本文的文献

1
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.非酒精性脂肪性肝病中的肠道微生物群:病理生理学、诊断与治疗
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
2
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病中肠道微生物群的作用机制及治疗进展
Gut Microbes. 2025 Dec;17(1):2500099. doi: 10.1080/19490976.2025.2500099. Epub 2025 May 20.
3
Cultivating complexity: Advancements in establishing in vitro models for the mucus-adhering gut microbiota.
培养复杂性:建立体外黏液附着肠道微生物群模型的进展。
Microb Biotechnol. 2024 Oct;17(10):e70036. doi: 10.1111/1751-7915.70036.
4
Lactobacillus helveticus attenuates alcoholic liver injury via regulation of gut microecology in mice.瑞士乳杆菌通过调节小鼠肠道微生态减轻酒精性肝损伤。
Microb Biotechnol. 2024 Oct;17(10):e70016. doi: 10.1111/1751-7915.70016.
5
and NAFLD: pathophysiology and therapy.以及非酒精性脂肪性肝病:病理生理学与治疗
Front Microbiol. 2024 Mar 20;15:1288856. doi: 10.3389/fmicb.2024.1288856. eCollection 2024.
6
Genetically Predicted Causal Effects of Gut Microbiota and Gut Metabolites on Digestive Tract Cancer: A Two-Sample Mendelian Randomization Analysis.肠道微生物群和肠道代谢物对消化道癌症的遗传预测因果效应:一项两样本孟德尔随机化分析
World J Oncol. 2023 Dec;14(6):558-569. doi: 10.14740/wjon1737. Epub 2023 Nov 3.